Drug-induced renal damage in preterm neonates: State of the art and methods for early detection

Drug Safety

Volumn 38, Issue 6, 2015, Pages 535-551

  Girardi, Anna ^a   Raschi, Emanuel ^a   Galletti, Silvia ^a   Poluzzi, Elisabetta ^a   Faldella, Giacomo ^a   Allegaert, Karel ^b   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b University Hospitals   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B; BETA 2 MICROGLOBULIN; BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CYSTATIN C; INTERLEUKIN 18; LOOP DIURETIC AGENT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPONTIN;

DRUG SAFETY; EARLY DIAGNOSIS; HUMAN; KIDNEY DEVELOPMENT; KIDNEY INJURY; METABOLOMICS; NEWBORN; NEWBORN INTENSIVE CARE; OFF LABEL DRUG USE; PREMATURITY; PRIORITY JOURNAL; REVIEW; CHEMICALLY INDUCED; INFANT, PREMATURE, DISEASES; KIDNEY DISEASES; NEONATAL INTENSIVE CARE UNIT;

EARLY DIAGNOSIS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; KIDNEY DISEASES; OFF-LABEL USE;

EID: 84927537260     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0288-6     Document Type: Review

References (129)

1. World Health Organization. Fact sheet on preterm birth. 2013. Available at: http://www.who.int/mediacentre/factsheets/fs363/en/. Accessed 15 Jan 2015.
2. Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics. 2012;129:1019–26.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) and Paediatric Committee (PDCO). Guideline on the investigation of medicinal products in the term and preterm neonate. 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003750.pdf. Accessed 15 Jan 2015.
4. Schreuder MF, Bueters RR, Allegaert K. The interplay between drugs and the kidney in premature neonates. Pediatr Nephrol. 2014;29:2083–91.
5. European Medicines Agency. The European paediatric initiative: history of the Paediatric Regulation. 2007. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003693.pdf. Accessed 15 Jan 2015.
6. US FDA. Modernization Act of 1997. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-105publ115/pdf/PLAW-105publ115.pdf. Accessed 15 Jan 2015.
7. European Medicines Agency. Better medicines for children. 2002. Available at: http://ec.europa.eu/health/files/pharmacos/docs/doc2002/feb/cd_pediatrics_en.pdf. Accessed 15 Jan 2015.
8. US FDA. Pediatric Research Equity Act. 2003. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-108publ155/html/PLAW-108publ155.htm. Accessed 15 Jan 2015.
9. Regulation on medicinal products for paediatric use. European Parliament and of the Council. 2006. Available at: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 15 Jan 2015.
10. European Medicines Agency. Better medicines for children from concept to reality: progress report on the Paediatric Regulation (EC) N°1901/2006. 2013. Available at: http://ec.europa.eu/health/files/paediatrics/2013_com443/paediatric_report-com%282013%29443_en.pdf. Accessed 15 Jan 2015.
11. US FDA. Food and Drug Administration Safety and Innovation Act (FDASIA). 2012. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/. Accessed 15 Jan 2015.
12. World Health Organization. WHO model formulary for children. Geneva: World Health Organization; 2010. Available at: http://www.who.int/selection_medicines/list/WMFc_2010.pdf. Accessed 15 Jan 2015.
13. Ministero della salute. Direzione generale della valutazione dei medicinali e della farmacovigilanza. Guida all'uso dei farmaci per i bambini. Rome: Istituto poligrafico e Zecca dello Stato; 2003 [SBN Code: SNT0002326].
14. US FDA. New pediatric labeling information database. Available at: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed 15 Jan 2015.
15. European Medicines Agency. Success of the Paediatric Regulation after 5 years. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500143984.pdf. Accessed 15 Jan 2015.
16. Laforgia N, Nuccio MM, Schettini F, Dell’aera M, Gasbarro AR, Dell’erba A, et al. Off-label and unlicensed drug use among neonatal intensive care units in Southern Italy. Pediatr Int. 2014;56:57–9.
17. Kieran EA, O’Callaghan N, O’Donnell CP. Unlicensed and off-label drug use in an Irish neonatal intensive care unit: a prospective cohort study. Acta Paediatr. 2014;103:e139–42.
18. Stiers JL, Ward RM. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr. 2014;168:106–8.
19. Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med. 2005;10:115–22.
20. Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168:130–6.
21. Kimland E, Nydert P, Odlind V, Bottiger Y, Lindemalm S. Paediatric drug use with focus on off-label prescriptions at Swedish hospitals: a nationwide study. Acta Paediatr. 2012;101:772–8.
22. Dell’Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci. 2007;29:361–7.
23. Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563–7.
24. Pansieri C, Bonati M, Choonara I, Jacqz-Aigrain E. Neonatal drug trials: impact of EU and US paediatric regulations. Arch Dis Child Fetal Neonatal Ed. 2014;99(5):F438.
25. Haslund-Krog S, Mathiasen R, Christensen HR, Holst H. The impact of legislation on drug substances used off-label in paediatric wards: a nationwide study. Eur J Clin Pharmacol. 2014;70:445–52.
26. Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation. J Clin Pharm Ther. 2014;39:144–53.
27. Dessi A, Salemi C, Fanos V, Cuzzolin L. Drug treatments in a neonatal setting: focus on the off-label use in the first month of life. Pharm World Sci. 2010;32:120–4.
28. Neubert A, Lukas K, Leis T, Dormann H, Brune L, Rascher W. Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol. 2010;66:87–95.
29. Pandolfini C, Bonati M. European paediatric research and children’s therapeutic needs. A trial review. Acta Paediatr. 2008;97:1232–7.
30. Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol. 2014;77:545–53.
31. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003;55:667–86.
32. European Medicines Agency. Discussion paper on the impact of renal immaturity when investigating medicinal products intended for paediatric use. European Medicines Agency (EMA). 2004. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003807.pdf. Accessed 15 Jan 2015.
33. Singh RR, Moritz KM, Bertram JF, Cullen-McEwen LA. Effects of dexamethasone exposure on rat metanephric development: in vitro and in vivo studies. Am J Physiol Renal Physiol. 2007;293:F548–54.
34. Lasaitiene D, Chen Y, Guron G, Marcussen N, Tarkowski A, Telemo E, Friberg P. Perturbed medullary tubulogenesis in neonatal rat exposed to renin-angiotensin system inhibition. Nephrol Dial Transplant. 2003;18:2534–41.
35. Gubler MC, Antignac C. Renin-angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int. 2010;77:400–6.
36. Kent AL, Maxwell LE, Koina ME, Falk MC, Willenborg D, Dahlstrom JE. Renal glomeruli and tubular injury following indomethacin, ibuprofen, and gentamicin exposure in a neonatal rat model. Pediatr Res. 2007;62:307–12.
37. Sutherland MR, Yoder BA, McCurnin D, Seidner S, Gubhaju L, Clyman RI, et al. Effects of ibuprofen treatment on the developing preterm baboon kidney. Am J Physiol Renal Physiol. 2012;302:F1286–92.
38. Rodriguez MM, Gomez AH, Abitbol CL, Chandar JJ, Duara S, Zilleruelo GE. Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatr Dev Pathol. 2004;7:17–25.
39. Sutherland MR, Gubhaju L, Moore L, Kent AL, Dahlstrom JE, Horne RS, et al. Accelerated maturation and abnormal morphology in the preterm neonatal kidney. J Am Soc Nephrol. 2011;22:1365–74.
40. Carmody JB, Charlton JR. Short-term gestation, long-term risk: prematurity and chronic kidney disease. Pediatrics. 2013;131:1168–79.
41. Musso CG, Ghezzi L, Ferraris J. Renal physiology in newborns and old people: similar characteristics but different mechanisms. Int Urol Nephrol. 2004;36:273–6.
42. Gubhaju L, Sutherland MR, Horne RS, Medhurst A, Kent AL, Ramsden A, et al. Assessment of renal functional maturation and injury in preterm neonates during the first month of life. Am J Physiol Renal Physiol. 2014;307:F149–58.
43. Jose PA, Fildes RD, Gomez RA, Chevalier RL, Robillard JE. Neonatal renal function and physiology. Curr Opin Pediatr. 1994;6:172–7.
44. Sulemanji M, Vakili K. Neonatal renal physiology. Semin Pediatr Surg. 2013;22:195–8.
45. Berg CS, Barnette AR, Myers BJ, Shimony MK, Barton AW, Inder TE. Sodium bicarbonate administration and outcome in preterm infants. J Pediatr. 2010;157:684–7.
46. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002;41:959–98.
47. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp Pharmacol. 2011;205:51–75.
48. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
49. Askenazi DJ, Koralkar R, Hundley HE, Montesanti A, Patil N, Ambalavanan N. Fluid overload and mortality are associated with acute kidney injury in sick near-term/term neonate. Pediatr Nephrol. 2013;28:661–6.
50. Koralkar R, Ambalavanan N, Levitan EB, McGwin G, Goldstein S, Askenazi D. Acute kidney injury reduces survival in very low birth weight infants. Pediatr Res. 2011;69:354–8.
51. Elmas AT, Tabel Y, Elmas ON. Serum cystatin C predicts acute kidney injury in preterm neonates with respiratory distress syndrome. Pediatr Nephrol. 2013;28:477–84.
52. Sarafidis K, Tsepkentzi E, Agakidou E, Diamanti E, Taparkou A, Soubasi V, et al. Serum and urine acute kidney injury biomarkers in asphyxiated neonates. Pediatr Nephrol. 2012;27:1575–82.
53. Walker MW, Clark RH, Spitzer AR. Elevation in plasma creatinine and renal failure in premature neonates without major anomalies: terminology, occurrence and factors associated with increased risk. J Perinatol. 2011;31:199–205.
54. Kandasamy Y, Smith R, Wright IM. Measuring cystatin C to determine renal function in neonates. Pediatr Crit Care Med. 2013;14:318–22.
55. Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney Int Suppl. 2005;97:S68–77.
56. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens. 1988;1:335–47.
57. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis. 1994;23:171–5.
58. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595–601.
59. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8:293–300.
60. D’Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63:809–25.
61. Hartman HA, Lai HL, Patterson LT. Cessation of renal morphogenesis in mice. Dev Biol. 2007;310:379–87.
62. Luyckx VA, Brenner BM. The clinical importance of nephron mass. J Am Soc Nephrol. 2010;21:898–910.
63. Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM. Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol. 2008;19:151–7.
64. White SL, Perkovic V, Cass A, Chang CL, Poulter NR, Spector T, et al. Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. Am J Kidney Dis. 2009;54:248–61.
65. Mammen C, Al AA, Skippen P, Nadel H, Levine D, Collet JP, et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis. 2012;59:523–30.
66. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003;290:1360–70.
67. Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJ. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6:477–9.
68. Taber SS, Pasko DA. The epidemiology of drug-induced disorders: the kidney. Expert Opin Drug Saf. 2008;7:679–90.
69. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78:743–50.
70. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta. 2005;351:31–47.
71. Zager RA. Pathogenetic mechanisms in nephrotoxic acute renal failure. Semin Nephrol. 1997;17:3–14.
72. Bennett WM, DeBroe ME. Analgesic nephropathy: a preventable renal disease. N Engl J Med. 1989;320:1269–71.
73. Griffin MD, Bergstralhn EJ, Larson TS. Renal papillary necrosis: a sixteen-year clinical experience. J Am Soc Nephrol. 1995;6:248–56.
74. Perazella MA. Drug-induced nephropathy: an update. Expert Opin Drug Saf. 2005;4:689–706.
75. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117:1979–87.
76. Gordon A, Jeffery HE. Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database Syst Rev. 2005;3:CD004501.
77. Patzer L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol. 2008;23:2159–73.
78. Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2011;11:CD005091.
79. Vieux R, Fresson J, Guillemin F, Hascoet JM. Perinatal drug exposure and renal function in very preterm infants. Arch Dis Child Fetal Neonatal Ed. 2011;96:F290–5.
80. Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol. 1998;9:506–15.
81. Wai AO, Lo AM, Abdo A, Marra F. Vancomycin-induced acute interstitial nephritis. Ann Pharmacother. 1998;32:1160–4.
82. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6:154–64.
83. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol. 2004;26:421–6.
84. Joannidis M. Drug-induced renal failure in the ICU. Int J Artif Organs. 2004;27:1034–42.
85. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002;49(Suppl 1):37–41.
86. Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy: is there a ‘right’ choice? Curr Opin Infect Dis. 2011;24:163–71.
87. Pacifici GM. Clinical pharmacology of furosemide in neonates: a review. Pharmaceuticals (Basel). 2013;6:1094–129.
88. Allegaert K, Anderson B, Simons S, van Overmeire B. Paracetamol to induce ductus arteriosus closure: is it valid? Arch Dis Child. 2013;98:462–6.
89. Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. J Matern Fetal Neonatal Med. 2009;22(Suppl 3):88–91.
90. Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev. 2010;12:CD000140.
91. Spitzer AR. Evidence-based methylxanthine use in the NICU. Clin Perinatol. 2012;39:137–48.
92. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112–21.
93. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307:275–82.
94. Sekine T, Endou H. Children’s toxicology from bench to bed: Drug-induced renal injury (3). Drug transporters and toxic nephropathy in childhood. J Toxicol Sci. 2009;34 Suppl 2:SP259–65.
95. Gallini F, Maggio L, Romagnoli C, Marrocco G, Tortorolo G. Progression of renal function in preterm neonates with gestational age < or = 32 weeks. Pediatr Nephrol. 2000;15:119–24.
96. Brion LP, Fleischman AR, McCarton C, Schwartz GJ. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth. J Pediatr. 1986;109:698–707.
97. Liborio AB, Branco KM, Torres de Melo BC. Acute kidney injury in neonates: from urine output to new biomarkers. Biomed Res Int. 2014;2014:601568.
98. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231–8.
99. Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devarajan P. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr. 2011;158:1009–15.
100. Wheeler DS, Devarajan P, Ma Q, Harmon K, Monaco M, Cvijanovich N, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med. 2008;36:1297–303.
101. Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care. 2007;11:R84.
102. Askenazi DJ, Montesanti A, Hunley H, Koralkar R, Pawar P, Shuaib F, et al. Urine biomarkers predict acute kidney injury and mortality in very low birth weight infants. J Pediatr. 2011;159:907–12.
103. La MG, Galletti S, Capelli I, Vandini S, Nisi K, Aquilano G, et al. Urinary neutrophil gelatinase-associated lipocalin at birth predicts early renal function in very low birth weight infants. Pediatr Res. 2011;70:379–83.
104. Askenazi DJ, Ambalavanan N, Goldstein SL. Acute kidney injury in critically ill newborns: what do we know? What do we need to learn? Pediatr Nephrol. 2009;24:265–74.
105. Cataldi L, Mussap M, Bertelli L, Ruzzante N, Fanos V, Plebani M. Cystatin C in healthy women at term pregnancy and in their infant newborns: relationship between maternal and neonatal serum levels and reference values. Am J Perinatol. 1999;16:287–95.
106. Sharma AP, Kathiravelu A, Nadarajah R, Yasin A, Filler G. Body mass does not have a clinically relevant effect on cystatin C eGFR in children. Nephrol Dial Transplant. 2009;24:470–4.
107. Li Y, Fu C, Zhou X, Xiao Z, Zhu X, Jin M, et al. Urine interleukin-18 and cystatin-C as biomarkers of acute kidney injury in critically ill neonates. Pediatr Nephrol. 2012;27:851–60.
108. Huang Y, Don-Wauchope AC. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: a systematic review. Inflamm Allergy Drug Targets. 2011;10:260–71.
109. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008–16.
110. Sprenkle P, Russo P. Molecular markers for ischemia, do we have something better then creatinine and glomerular filtration rate? Arch Esp Urol. 2013;66:99–114.
111. Parikh CR, Thiessen-Philbrook H, Garg AX, Kadiyala D, Shlipak MG, Koyner JL, et al. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol. 2013;8:1079–88.
112. Hoffmann A, Nimtz M, Conradt HS. Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology. 1997;7:499–506.
113. Filler G, Priem F, Lepage N, Sinha P, Vollmer I, Clark H, et al. Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem. 2002;48:729–36.
114. Bariciak E, Yasin A, Harrold J, Walker M, Lepage N, Filler G. Preliminary reference intervals for cystatin C and beta-trace protein in preterm and term neonates. Clin Biochem. 2011;44:1156–9.
115. Zwiers AJ, Cransberg K, de Rijke YB, Willemsen SP, de Mol AC, Tibboel D, et al. Reference ranges for serum beta-trace protein in neonates and children younger than 1 year of age. Clin Chem Lab Med. 2014;52:1815–21.
116. Trof RJ, Di MF, Leemreis J, Groeneveld AB. Biomarkers of acute renal injury and renal failure. Shock. 2006;26:245–53.
117. Fanos V, Antonucci R, Barberini L, Noto A, Atzori L. Clinical application of metabolomics in neonatology. J Matern Fetal Neonatal Med. 2012;25(Suppl 1):104–9.
118. Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, et al. From pediatric covariate model to semiphysiological function for maturation: part I. Extrapolation of a covariate model from morphine to zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012;1:e9.
119. Krekels EH, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, et al. From pediatric covariate model to semiphysiological function for maturation: part II. Sensitivity to physiological and physicochemical properties. CPT Pharmacometrics Syst Pharmacol. 2012;1:e10.
120. Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician’s request for a more integrated approach. J Biomed Biotechnol. 2012;2012:103763.
121. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl 1):5–16.
122. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006;165:741–6.
123. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819–29.
124. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51:105–17.
125. De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31:754–67.
126. Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol. 2004;28:132–40.
127. Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med. 2004;144:285–93.
128. Hanna MH, Brophy PD. Metabolomics in pediatric nephrology: emerging concepts. Pediatr Nephrol. 2014. doi:10.1007/s00467-014-2880-x.
129. Fanos V, Fanni C, Ottonello G, Noto A, Dessi A, Mussap M. Metabolomics in adult and pediatric nephrology. Molecules. 2013;18:4844–57.